All In Biotech

Drug Trial Radar · NCT05465954

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

Efficacy and Safety Study of Neoadjuvant Efineptakin Alfa (NT-I7) and Pembrolizumab in Recurrent Glioblastoma

Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

53

Actual

Start

Jan 24, 2023

Primary completion

Sep 2, 2026

Study completion Sep 2, 2031

Sponsor

Lead sponsor
Mayo ClinicAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
NeoImmuneTech; Merck Sharp & Dohme LLC; National Cancer Institute (NCI)
First posted
Jul 20, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial tests the safety and side effects of efineptakin alfa and pembrolizumab in treating patients with glioblastoma that has come back (recurrent). Efineptakin alfa is an immunotherapy drug that works by helping the immune system fight tumor cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving efineptakin alfa and pembrolizumab may kill more tumor cells in patients with recurrent glioblastoma.

Conditions

  • High Grade Astrocytic Tumor
  • Recurrent Glioblastoma, IDH-Wildtype
  • Recurrent Gliosarcoma

Interventions

  • Biospecimen CollectionProcedure

    Correlative studies

  • Efineptakin alfaBiological

    Given IM

  • PembrolizumabBiological

    Given IV

  • BiopsyProcedure

    Undergo tumor biopsy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival rateTime frame: Up to 9 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic

    Rochester, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.